Other studies have shown that treatment of MM with the anti-resorptive bone agent, zoledronic acid 107, and the Receptor Activator of NF-kB ligand (RANKL) inhibitor, denosumab 32 reduced osteolysis and inhibited MM progression 108. This evidence concerns the gene TNFSF11 and Miyoshi myopathy.